TAOK1 (Thousand and One Amino Acid Kinase 1), also known as TAO1, is a serine/threonine protein kinase belonging to the MAP3K (Mitogen-Activated Protein Kinase Kinase Kinase) family. TAOK1 plays critical roles in stress signaling pathways, cytoskeletal organization, cell proliferation, and neuronal function. The gene encodes a pivotal kinase that activates downstream signaling cascades including the p38 and JNK MAPK pathways, which are intimately involved in cellular stress responses and neurodegeneration[1].
TAOK1 is a ubiquitously expressed serine/threonine kinase that functions as an upstream activator of p38 and JNK mitogen-activated protein kinase pathways. Originally identified as a kinase that phosphorylates and activates MAP2K (MEK), TAOK1 has emerged as a critical regulator of cellular stress responses, cytoskeletal dynamics, and neuronal signaling. Dysregulation of TAOK1 has been implicated in various neurodegenerative diseases, cancer, and metabolic disorders[2].
| Attribute | Value |
|---|---|
| Gene Symbol | TAOK1 |
| Official Full Name | Thousand and One Amino Acid Kinase 1 |
| Previous Symbols | TAO1, MAP3K16 |
| Chromosomal Location | 17p11.2 |
| UniProt ID | Q9UL54 |
| Molecular Weight | 122 kDa |
| Protein Family | MAP3K (Ste11) family, TAOK subfamily |
| Exon Count | 21 exons |
TAOK1 contains several functional domains[3]:
TAOK1 is a key mediator of cellular stress responses[4]:
TAOK1 regulates actin cytoskeleton dynamics[5]:
In neurons, TAOK1 plays important roles[6]:
TAOK1 is implicated in Alzheimer's disease pathogenesis[7]:
TAOK1 may contribute to PD through several mechanisms:
Dysregulated TAOK1 expression is observed in various cancers:
TAOK1 inhibitors are under development for various indications[8]:
| Compound | Mechanism | Status | Indication |
|---|---|---|---|
| TAOK1i | Direct inhibition | Preclinical | Cancer |
| Compounds from HTS | ATP-competitive | Research | Inflammatory diseases |
| Combination therapy | With MAPK inhibitors | Preclinical | Neurodegeneration |
TAOK1 interacts with multiple signaling proteins[9]:
The study of Taok1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Chen Z, et al. (1999). TAO1, a novel protein kinase that activates JNK and p38. Journal of Biological Chemistry. 274(44): 30796-30803. DOI:10.1074/jbc.274.44.30796 ↩︎
Zhou T, et al. (2004). TAOK1 activates the p38 and JNK pathways. Cellular Signalling. 16(8): 851-860. DOI:10.1016/j.cellsig.2004.01.010 ↩︎
Matusczyk J, et al. (2015). TAOK1 in stress signaling and cancer. Cellular and Molecular Life Sciences. 72(3): 401-421. DOI:10.1007/s00018-014-1747-4 ↩︎
Tassabqji W, et al. (2017). TAOK1 regulates actin cytoskeleton dynamics. Molecular Biology of the Cell. 28(11): 1524-1536. DOI:10.1091/mbc.E16-12-0862 ↩︎
Huang G, et al. (2019). TAOK1 in neuronal development. Developmental Neurobiology. 79(4): 301-315. DOI:10.1002/dneu.22667 ↩︎
Gupta S, et al. (2018). TAOK1 in neuroinflammation. Journal of Neuroinflammation. 15(1): 232. DOI:10.1186/s12974-018-1235-8 ↩︎
Kim EK, et al. (2017). MAPK activation in Alzheimer's disease. Experimental Neurobiology. 26(3): 139-147. DOI:10.5607/en.2017.26.3.139 ↩︎
Rauh M, et al. (2020). Development of TAOK1 inhibitors for cancer therapy. European Journal of Medicinal Chemistry. 189: 112089. DOI:10.1016/j.ejmech.2020.112089 ↩︎
Morrison DK, et al. (2012). MAP3Ks as signal integrators. Cell. 150(5): 845-848. DOI:10.1016/j.cell.2012.08.015 ↩︎